In this episode of CardiaCast, Dr. Michael Blaha will be joined by Dr. Ann Marie Navar to discuss the 2026 updates to ACC/AHA guideline on management of dyslipidemia and key clinical trial data supporting the use of PCSK9 inhibitors in getting patients to their lipid goals. They discuss available PCSK9 inhibitors, including the recently approved injectable PCSK9 inhibitor lerodalcibep-liga. After discussing the limitations and barriers associated with injectable PCSK9 inhibitors, they will introduce the emerging oral PCSK9 inhibitors and explore the latest clinical data for enlicitide and AZD0780.

This podcast was developed by the American College of Cardiology Foundation and Med-IQ and supported by an educational grant from Merck.

Related References:

1. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. Published online March 13, 2026. doi:10.1016/j.jacc.2025.11.016
2. Bohula EA, Marston NA, Bhatia AK, et al. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. N Engl J Med. 2026;394(2):117-127. doi:10.1056/NEJMoa2514428
3. Marston NA, Bohula EA, Bhatia AK, et al. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial. JAMA. 2026;335(16):1400-1407. doi:10.1001/jama.2026.3277
4. Klug EQ, Llerena S, Burgess LJ, et al; LIBERATE-HR Investigators. Efficacy and safety of Lerodalcibep in patients with or at high risk of cardiovascular disease: A randomized clinical trial. JAMA Cardiol. 2024;9(9):800-807
5. Koren MJ, Vega RB, Agrawal N, et al. An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial. J Am Coll Cardiol. 2025;85(21):1996-2007. doi:10.1016/j.jacc.2025.03.499
6. Navar AM, Mikhailova E, Catapano AL, et al; CORALreef Lipids Investigators. A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide. N Engl J Med. 2026;394(6):529-539